Cefaclor Anhydrous

Cefaclor Anhydrous

SCHEMBL49912

N[C@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Cefaclor Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 1.00
HSD17B10 Q99714 7/20 1.00
MAPT P10636 7/20 1.00
KMT2A Q03164 6/20 1.00
KDM4E B2RXH2 5/20 1.00
MEN1 O00255 5/20 1.00
CYP3A4 P08684 4/20 1.00
HPGD P15428 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
SLC15A2 Q16348 3/20 1.00
CYP2C9 P11712 2/20 1.00
LMNA P02545 2/20 1.00
NR1I2 O75469 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
CTDSP1 Q9GZU7 1/20 1.00
HIF1A Q16665 1/20 1.00
CYP2C19 P33261 2/20 0.77
BLM P54132 1/20 0.77
MAPK1 P28482 1/20 0.77
ADRA1A P35348 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefaclor Anhydrous SCHEMBL33540 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL8626211 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL8524989 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL8943624 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL6155629 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL16072812 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL8478823 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL1006419 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL8626208 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E
Cefaclor Anhydrous SCHEMBL27281884 1.00 ALDH1A1 (1.00) ALDH1A1HSD17B10MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2588 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027140-A1 COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA ATOPIC MEDICAL INC (US) 2026-01-29 US claimed
US-12465623-B2 Use of parasites and extracellular vesicles obtained from parasites in cancer treatment YEDITEPE UNIVERSITESI (TR) 2025-11-11 US claimed
EP-3965808-B1 USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT UNIV YEDITEPE (TR) 2025-09-03 EP claimed
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof RECREO PHARMACEUTICALS LLC (US) 2025-07-29 US claimed
EP-4338799-A2 TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY Regents of the University of Minnesota (US) 2024-03-20 EP claimed
US-20240082370-A1 SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION THERIVA BIOLOGICS, INC. 2024-03-14 US claimed
US-20230414584-A1 ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS CENTRE FOR DIGESTIVE DISEASES (AU) 2023-12-28 US claimed
EP-3529359-B1 TUMOR INFILTRATING LYMPHOCYTES FOR USE IN THERAPY UNIV MINNESOTA (US) 2023-12-13 EP claimed
CN-116650492-A Administration of antibiotic compounds for the treatment of streptococcal infections to treat psoriasis 消化系统疾病中心 2023-08-29 CN claimed
US-20220226393-A1 USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT YEDITEPE UNIVERSITESI (TR) 2022-07-21 US claimed
EP-1244471-A1 LIQUID COMPOSITION OF BIODEGRADABLE BLOCK COPOLYMER FOR DRUG DELIVERY SYSTEM AND PROCESS FOR THE PREPARATION THEREOF Samyang Corporation (KR) 2002-10-02 EP claimed
US-20020042394-A1 Cobalamin compounds useful as antibiotic agents and as imaging agents HOGENKAMP HENRICUS P C (US) 2002-04-11 US claimed
WO-2001092288-A2 COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-12-06 WO claimed
WO-2001045742-A1 LIQUID COMPOSITION OF BIODEGRADABLE BLOCK COPOLYMER FOR DRUG DELIVERY SYSTEM AND PROCESS FOR THE PREPARATION THEREOF SAMYANG CORPORATION (KR) 2001-06-28 WO claimed
US-6060268-A PROVIDES A HIGHER SYNTHESIS/HYDROLYSIS RATIO; FOR PRODUCTION OF BETA-LACTAM DERIVATIVES SUCH AS CEPHALOSPORINS AND PENICILLINS BY REACTING AN AMINO BETA-LACTAM WITH AN ACYLATING AGENT IN THE PRESENCE OF THE IMMOBILIZED ENZYME GIST-BROCADES B.V. (NL) 2000-05-09 US claimed
EP-0839192-A1 AN IMPROVED IMMOBILIZED PENICILLIN G ACYLASE GIST-BROCADES B.V. (NL) 1998-05-06 EP claimed
WO-1997004086-A1 AN IMPROVED IMMOBILIZED PENICILLIN G ACYLASE GIST-BROCADES B.V. (NL) 1997-02-06 WO claimed
US-5354556-A Microparticles in form of micromatrix with active ingredient uniformly distributed in nontoxic polymer suspended in aqueous vehicle containing substance which inhibits release during storage ELAN CORPORATION, PLC (IE) 1994-10-11 US claimed
EP-0280571-B1 SUSTAINED RELEASE MATRIX FORMULATIONS ELI LILLY AND COMPANY (US) 1993-08-04 EP claimed
US-4952402-A EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS ELAN CORPORATION, P.L.C. (IE) 1990-08-28 US claimed